Show simple item record

dc.contributor.authorAdalsteinsson, Jonas A
dc.contributor.authorMuzumdar, Sonal
dc.contributor.authorWaldman, Reid
dc.contributor.authorWu, Rong
dc.contributor.authorRatner, Désirée
dc.contributor.authorFeng, Hao
dc.contributor.authorUngar, Jonathan
dc.contributor.authorSilverberg, Jonathan I
dc.contributor.authorOlafsdottir, Gudridur H
dc.contributor.authorKristjansson, Arni Kjalar
dc.contributor.authorTryggvadottir, Laufey
dc.contributor.authorJonasson, Jon Gunnlaugur
dc.date.accessioned2021-10-08T12:25:34Z
dc.date.available2021-10-08T12:25:34Z
dc.date.issued2021-02-19
dc.date.submitted2021-10
dc.identifier.citationAdalsteinsson JA, Muzumdar S, Waldman R, Wu R, Ratner D, Feng H, Ungar J, Silverberg JI, Olafsdottir GH, Kristjansson AK, Tryggvadottir L, Jonasson JG. Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. J Am Acad Dermatol. 2021 Jul;85(1):56-61. doi: 10.1016/j.jaad.2021.02.042.en_US
dc.identifier.pmid33610593
dc.identifier.doi10.1016/j.jaad.2021.02.042
dc.identifier.urihttp://hdl.handle.net/2336/621894
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractBackground: Metformin has anticarcinogenic properties and is also known to inhibit the sonic hedgehog pathway, but population-based studies analyzing the potential protective effect for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are needed. Objectives: To delineate the association between metformin use and invasive SCC, SCC in situ (SCCis), and BCC. Methods: A population-based case-control study design was employed using all 6880 patients diagnosed in Iceland between 2003-2017 with first-time BCC, SCCis, or invasive SCC, and 69,620 population controls. Multivariate odds ratios (ORs) were calculated using conditional logistic regression. Results: Metformin was associated with a lower risk of developing BCC (OR, 0.71; 95% confidence interval [CI], 0.61-0.83), even at low doses. No increased risk of developing SCC was observed. SCCis risk was mildly elevated in the 501-1500 daily dose unit category (OR, 1.40; 95% CI, 1.00-1.96). Limitations: This study was retrospective in nature with the inability to adjust for ultraviolet exposure, Fitzpatrick skin type, and comorbidities. Conclusion: Metformin is associated with decreased risk of BCC development, even at low doses. Metformin might have potential as a chemoprotective agent for patients at high risk of BCC, although this will need confirmation in future studies. Keywords: basal cell carcinoma; keratinocyte carcinoma; metformin; squamous cell carcinoma; squamous cell carcinoma in situ.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S0190962221004011?via%3Dihuben_US
dc.rightsCopyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
dc.subjectbasal cell carcinomaen_US
dc.subjectkeratinocyte carcinomaen_US
dc.subjectmetforminen_US
dc.subjectsquamous cell carcinomaen_US
dc.subjectsquamous cell carcinoma in situen_US
dc.subjectHúðkrabbameinen_US
dc.subject.meshCarcinoma, Basal Cellen_US
dc.subject.meshMetforminen_US
dc.titleMetformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland.en_US
dc.typeArticleen_US
dc.identifier.eissn1097-6787
dc.contributor.department1Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Dermatology, University of Connecticut, Farmington, Connecticut. Electronic address: adalsteinsson@uchc.edu. 2Department of Dermatology, University of Connecticut, Farmington, Connecticut. 3Connecticut Convergence Institute for Translation in Regenerative Engineering, Farmington, Connecticut. 4Department of Dermatology, New York University Langone Health, New York, New York. 5Mount Sinai Department of Dermatology, New York, New York. 6The George Washington University School of Medicine and Health Sciences, Washington, DC. 7Icelandic Cancer Registry, Reykjavik, Iceland. 8Department of Pathology, Landspitali National-University Hospital, Reykjavik, Iceland. 9Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Icelandic Cancer Registry, Reykjavik, Iceland. 10Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Department of Pathology, Landspitali National-University Hospital, Reykjavik, Iceland.en_US
dc.identifier.journalJournal of the American Academy of Dermatologyen_US
dc.rights.accessNational Consortium - Landsaðganguren_US
dc.departmentcodeDAV12
dc.departmentcodePTT12
dc.source.journaltitleJournal of the American Academy of Dermatology
dc.source.volume85
dc.source.issue1
dc.source.beginpage56
dc.source.endpage61
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record